Press Releases

Press Releases

Date	Title	View
September 29, 2022	NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
August 29, 2022	AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 11, 2022	AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
June 29, 2022	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
May 10, 2022	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
March 24, 2022	AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
March 16, 2022	AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
February 16, 2022	AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
February 10, 2022	AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole

Investors